LFLuís Manuel Fernández-Domínguez

Luís Manuel Fernández-Domínguez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luís Manuel Fernández-Domínguez has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Felisa López-Azcona

    Autoimmunity, Infection and Thrombosis Research Group (GRAIIT), Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut de Recerca Biomèdica Catalunya Sud, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications
  • Antoni Castro

    Autoimmunity, Infection and Thrombosis Research Group (GRAIIT), Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut de Recerca Biomèdica Catalunya Sud, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications
  • Antonio Peralta-Vázquez

    Department of Internal Medicine, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, 43204 Reus, Spain

    2 shared publications
  • Carles García-Cervera

    Department of Internal Medicine, Institut d’Investigació Sanitària Pere Virgili, Hospital Universitari de Sant Joan, Universitat Rovira i Virgili, 43204 Reus, Spain

    2 shared publications
  • Jordi Camps

    Unitat de Recerca Biomédica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications
  • Jorge Joven

    Unitat de Recerca Biomédica, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, 43204 Reus, Spain

    2 shared publications

Latest Publications

  • Open Access

    Retrospective Analysis of Clostridioides difficile Infection Rates and Outcomes in Hospitalized Patients during the COVID-19 Pandemic: A Unicenter Study in Reus, Spain

    by Simona Iftimie, Ana F. López-Azcona, Mireia Corchero-Valverde, Antonio Peralta-Vázquez, Laia Revuelta López-Cordón, Carles García-Cervera, Luís Manuel Fernández-Domínguez, Jordi Camps, Jorge Joven, Antoni Castro

    Background: Clostridioides difficile infections (CDI) vary in severity from mild diarrhea to life-threatening conditions like pseudomembranous colitis or toxic megacolon, often leading to sepsis and death. The COVID-19 pandemic prompted changes in healthcare practices, potentially affecting CDI incidence, though reported data are inconclusive. We studied factors influencing CDI incidence and outcomes at a university hospital throughout the COVID-19 pandemic years. Methods: We conducted a retrospective study on all adult hospitalized CDI cases from 1 January 2020 to 31 December 2022 in Hospital Universitari de Sant Joan in Reus. We collected demographic information, comorbid conditions, and concurrent infections. Results: While overall CDI and COVID-19 rates decreased in 2022, a notable increase in CDI infections was observed among oncological patients and those undergoing some aggressive treatments, such as colonoscopies or gastroscopies. The prevalence of comorbidities remained unmodified, and there were declines in prior gastrointestinal surgeries and proton pump inhibitor prescriptions. Factors associated with patient fatality or prolonged hospitalization included older age, cancer, chronic kidney disease, higher Charlson and McCabe indices, elevated C-reactive protein, and low albumin concentrations. Conclusions: Our study shows the evolving landscape of CDI during the COVID-19 pandemic and emphasizes the impact of delayed diagnoses and treatments exacerbated by telemedicine adoption. Identified risk factors for CDI-related mortality or prolonged hospital stays underscore the importance of targeted interventions in high-risk populations.


  • Open Access

    Retrospective Analysis of Clostridioides difficile Infection Rates in Hospitalized Patients during COVID-19 Pandemic. A Unicenter Study in Reus, Spain

    by Simona Iftimie, Ana F. López-Azcona, Mireia Corchero-Valverde, Antonio Peralta-Vázquez, Laia Revuelta López-Cordón, Carles García-Cervera, Luís Manuel Fernández-Domínguez, Jordi Camps, Jorge Joven, Antoni Castro

    .Background: Clostridioides difficile infections (CDI) vary in severity from mild diarrhea to life-threatening conditions like pseudomembranous colitis or toxic megacolon, often leading to sepsis and death. The COVID-19 pandemic prompted changes in healthcare practices, potentially affecting CDI incidence, though reported data are inconclusive. We studied factors influencing CDI incidence and outcomes at a university hospital throughout the COVID-19 pandemic years. Methods: We conducted a retrospective study on all adult hospitalized CDI cases from January 1, 2020, to December 31, 2022. We collected demographic information, comorbid conditions, and concurrent infections. Results: While overall CDI and COVID-19 rates decreased in 2022, a nota-ble increase in CDI infections was observed among oncological patients and those undergoing some aggressive treatments, such as colon or gastroscopies. The prevalence of comorbidities remained unmodified, and there were declines in prior gastrointestinal surgeries and proton pump inhibitor prescriptions. Factors associated with patient fatality or prolonged hospitaliza-tion included older age, cancer, chronic kidney disease, higher Charlson and McCabe indices, elevated C-reactive protein, and low albumin concentrations. Conclusion: Our study shows the evolving landscape of CDI during the COVID-19 pandemic and emphasizes the impact of de-layed diagnoses and treatments exacerbated by telemedicine adoption. Identified risk factors for CDI-related mortality or prolonged hospital stays underscore the importance of targeted inter-ventions in high-risk populations.